N. Lynn Henry
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
398
Citations
12,443
Est. group size
~17
Recurring co-author estimate
Active years
50
Publishing since 1977
Typically publishes in teams of ~12 · 9% small-team papers (≤3 authors) · across 48 venues
- Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610.
Journal of Clinical Oncology · 2026
- Immune checkpoint inhibitor (ICI) toxicity in a large prospective cohort of patients with solid tumors: The I-CHECKIT study (SWOG S2013).
Journal of Clinical Oncology · 2026
- A risk prediction model for severe, life-threatening, and fatal treatment-related toxicity.
Journal of Clinical Oncology · 2026
- Vitamin D insufficiency and risk of taxane-induced peripheral neuropathy: Results from SWOG S1714.
Journal of Clinical Oncology · 2026
- The association of baseline fatigue and severe cancer treatment toxicity by comorbid conditions: A pooled analysis.
Journal of Clinical Oncology · 2026
- Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).
Journal of Clinical Oncology · 2026
- A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2– breast cancer and Oncotype recurrence score ≤ 25 (OFSET): NRG-BR009.
Journal of Clinical Oncology · 2026
- Trends in ovarian function suppression use among premenopausal women with breast cancer: A longitudinal analysis from 2015-2023.
Journal of Clinical Oncology · 2026
- Longitudinal multi-omics analyses of chemotherapy-induced peripheral neuropathy in response to taxanes
BMC Cancer · 2025
- Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial
JNCI Cancer Spectrum · 2025
- Play Together? Unveiling Facilitators and Barriers to Inclusive Outdoor Play for Dutch Children With and Without Disabilities: A Qualitative Study
Child Care Health and Development · 2025
- Rural–Urban Disparities in Cancer Care—Analyzing Routinely Collected Patient‐Reported Outcomes. A Cross‐Sectional Study
Cancer Medicine · 2025
- Clinician and Patient Perspectives on a Patient-Facing Online Breast Cancer Symptom Visualization Tool
JCO Clinical Cancer Informatics · 2025
- Risks of adverse health outcomes among older rural prostate cancer survivors in the SEER‐Medicare data
The Journal of Rural Health · 2025
- Hidden Costs of Endocrine Therapy for Black Breast Cancer Survivors: A Qualitative Examination of Patient and Provider Experiences
Clinical Breast Cancer · 2025
- Journal of Clinical Oncology×73
- Breast Cancer Research and Treatment×17
- Cancer Research×10
- Pharmacogenomics×7
- Cancer×6
- Connor Ward
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Thomas Helland
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Santosh Philips
Biochemistry, Genetics and Molecular Biology · Indiana University
- Kelley M. Kidwell
Biochemistry, Genetics and Molecular Biology · University of Michigan
- James M. Rae
Biochemistry, Genetics and Molecular Biology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile